Key Takeaways:
- MiMedx reported Q2 revenue of $64.4M, missing the $64.7M consensus.
- EPS came in at -$0.05, slightly below the -$0.0485 estimate.
- The miss marks a rare earnings disappointment for the wound-care company.
Quay lại
MiMedx misses Q2 estimates with $64.4M revenue and $0.05 loss
MiMedx Group reported Q2 revenue of $64.4 million, missing the $64.7 million consensus estimate by 0.6%.
"The quarter reflects the ongoing challenges in the wound-care market," Chief Executive Officer Joseph H. Capper said in a statement.
Earnings per share came in at -$0.05, compared with the -$0.0485 average analyst estimate, a miss of $0.0015 per share. Revenue of $64.36 million fell short of the $64.73 million analysts had projected, a gap of about $370,000.
The miss marks a rare earnings disappointment for the Marietta, Georgia-based regenerative medicine company, which has focused on expanding its portfolio of tissue grafts and wound-healing products. MiMedx did not disclose updated guidance for the remainder of the fiscal year. The company's next catalyst will be its Q3 earnings report, where investors will look for signs of revenue acceleration and margin improvement.
This article is for informational purposes only and does not constitute investment advice.
